Skip to main content

Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer

Journal of Cancer Research and Clinical Oncology volume 141, pages 161–168 (2015)Cite this article

Abstract

Purpose

We investigated whether the European Organization for Research and Treatment of Cancer (EORTC) scoring system can be used for the selection of adjuvant intravesical therapies for individual patients who undergo transurethral resection (TURB) for non-muscle-invasive bladder cancer (NMIBC).

Methods

We retrospectively analyzed the data of 469 TURB cases for NMIBC. Clinical and pathological variables were compared using univariate and multivariate Cox proportional hazards regression analyses. The recurrence-free survival (RFS) rate was estimated by the Kaplan–Meier method, and the log-rank test was used to compare groups divided according to EORTC score or type of adjuvant therapy.

Results

The overall RFS rate at 1 and 3 years was 59.1 and 40.3 %, respectively. Of the total, 424 TURB cases (90.4 %) had an EORTC score of 1–9. Tumor number, size, and grade were significant predictors of time to recurrence. The EORTC score was a significant predictor of RFS according to multivariate analysis, and the hazard ratios increased according to each EORTC score in multivariate analysis of a combination of EORTC score and adjuvant therapies. In groups with intermediate recurrence risk as defined by the European Association of Urology guidelines, the recurrence prevention effects in patients with an EORTC score of ≥5 were significantly greater with intravesical Bacillus Calmette-Guérin therapy than with weekly intravesical chemotherapy.

Conclusion

The EORTC scoring system provides useful information for the selection of adjuvant therapies for patients at intermediate risk of NMIBC recurrence.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  • Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639–653

    PubMed  Article  Google Scholar 

  • Bohle A, Jocham D, Bock PR et al (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95

    CAS  PubMed  Article  Google Scholar 

  • Brausi M, Witjes JA, Lamm D et al (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186:2158–2167

    PubMed  Article  Google Scholar 

  • Ehdale B, Sylvester R, Herr HW (2013) Maintenance bacillus Calmette-Guerin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 64:579–585

    Article  Google Scholar 

  • Faba OR, Palou J, Breda A, Villavicencio H (2012) High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol 30:833–840

    PubMed  Article  Google Scholar 

  • Friedrich MG, Pichlmeier U, Schwaibold H et al (2007) Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52:1123–1129

    CAS  PubMed  Article  Google Scholar 

  • Gudjónsson S, Adell L, Merdasa F et al (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The result of a prospective randomised multicentre study. Eur Urol 55:773–780

    PubMed  Article  Google Scholar 

  • Hernández V, De La Peña E, Martin MD et al (2011) External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol 29:409–414

    PubMed  Article  Google Scholar 

  • Hisataki T, Miyao N, Masumori N et al (2001) Risk factors for multiple intravesical recurrence of superficial bladder cancer. Urology 58:935–939

    CAS  PubMed  Article  Google Scholar 

  • Kikuchi E, Fujimoto H, Mizutani Y et al (2009) Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999–2001 report from the Japanese urological association. Int J Urol 16:279–286

    PubMed  Article  Google Scholar 

  • Malmström PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle invasive bladder cancer. Eur Urol 56:247–256

    PubMed  Article  Google Scholar 

  • Mostofi FK, Sobin LH, Torloni H (1973) Histological typing of urinary bladder tumours. World Health Organization, Geneva

    Google Scholar 

  • Pillai R, Wang D, Mayer EK, Abel P (2011) Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort. Sci World J 11:751–759

    Article  Google Scholar 

  • Sakano S, Matsuyama H, Takai K et al (2011) Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European association of urology. BJU Int 107:1598–1604

    PubMed  Article  Google Scholar 

  • Sobin LH, Wittekind C (1997) TNM classification of malignant tumors, 5th edn. Wiley-Liss Inc, New York

    Google Scholar 

  • Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published result of randomized clinical trials. J Urol 171(6 Pt 1):2186–2190

    PubMed  Article  Google Scholar 

  • Sylvester R, Van der Mejiden A, Oosterlinck W, et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–475; discussion 475–477

  • Sylvester RJ, Brausi MA, Kirkels WJ et al (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage TaT1 urothelial carcinoma of the bladder. Eur Urol 57:766–773

    PubMed Central  PubMed  Article  Google Scholar 

  • van Rhijn BW, Burger M, Lotan Y et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430–442

    PubMed  Article  Google Scholar 

  • Xu T, Zhu Z, Zhang X, Wang X et al (2013) Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. Urology 82:387–393

    PubMed  Article  Google Scholar 

Download references

Conflict of interest

None declared.

Author information

Affiliations

  1. Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Takaramachi 13-1, Kanazawa, Ishikawa, 920-8640, Japan

    Mitsuo Ofude, Yasuhide Kitagawa, Hiroshi Yaegashi, Kouji Izumi, Satoru Ueno, Yoshifumi Kadono, Hiroyuki Konaka, Atsushi Mizokami & Mikio Namiki

Authors
  1. Mitsuo Ofude
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuhide Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Yaegashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kouji Izumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoru Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshifumi Kadono
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyuki Konaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atsushi Mizokami
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mikio Namiki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuhide Kitagawa.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ofude, M., Kitagawa, Y., Yaegashi, H. et al. Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer. J Cancer Res Clin Oncol 141, 161–168 (2015). https://doi.org/10.1007/s00432-014-1795-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-014-1795-z

Keywords

  • Bacillus Calmette-Guérin
  • European Organization for Research and Treatment of Cancer scoring system
  • Non-muscle-invasive bladder cancer
  • Recurrence risk predictor